Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 5, 2020

Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined

GlobeNewswire October 22, 2020

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined

GlobeNewswire October 9, 2020

Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

GlobeNewswire October 5, 2020

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

GlobeNewswire October 1, 2020

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire August 3, 2020

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

GlobeNewswire June 24, 2020

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

GlobeNewswire June 2, 2020

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

GlobeNewswire June 2, 2020

Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

GlobeNewswire May 19, 2020

Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results

GlobeNewswire May 4, 2020

Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 9, 2020

Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference

GlobeNewswire February 24, 2020

Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 19, 2020

Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer

GlobeNewswire February 6, 2020

Aduro Biotech Announces Corporate Restructuring

GlobeNewswire January 9, 2020

1st International Jatiluhur Jazz Festival brings World Jazz to Jatiluhur Dam

ACN Newswire November 25, 2019

Jatiluhur Jazz Festival 2019, World Jazz at the Jatiluhur Dam

ACN Newswire November 22, 2019

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

GlobeNewswire November 8, 2019

Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 7, 2019